Skip to main content
. 2017 Jun 28;8(37):61944–61957. doi: 10.18632/oncotarget.18734

Figure 4. Catalytic activity of SRPK1 was critical in promoting tumor progression.

Figure 4

(A) Immunoblotting results revealed that wild type SRPK1 (WT) overexpression increased the protein levels of epithelial-mesenchymal transition (EMT) biomarkers. However, transfection of the kinase-dead mutant of SRPK1 (KDM) showed no significant oncogenic alteration on Slug and Twist1. (B) The mRNA levels of EMT markers were tested by RT-qPCR and showed comparable results with protein levels. Overexpression of SRPK1-KDM neither showed effect on cell proliferation (C) nor invasion (D), compared with control groups.